ArticleLipids in health and disease2026
The clinical application of parenteral nutrition with Omega-3 fatty acids in patients after gastrectomy: a retrospective cohort study and cost-effectiveness analysis.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative complications of gastrectomy severely impact patient prognosis and impose a substantial economic burden. This study aims to assess the effect of adding omega-3 fish oil emulsion to parenteral nutrition on clinical outcomes and cost-effectiveness in gastric cancer populations after gastrectomy.
methodsThis retrospective cohort study included 150 gastric cancer patients after gastrectomy at Nanjing Drum Tower Hospital between September 2022 and September 2023. Patients were assigned to an omega-3 group and a control group based on whether they received postoperative omega-3 fish oil fat emulsion injection, with 53 matched pairs after propensity score matching (PSM). The primary outcome was the incidence of Grade II or higher complications. An economic evaluation was conducted from a hospital perspective, considering only direct medical costs over a 90-day horizon without discounting, using the incremental cost-effectiveness ratio (ICER). To evaluate the robustness of the primary findings, sensitivity analyses were performed using both one-way and probabilistic methods.
resultsAfter PSM, the omega-3 group demonstrated markedly lower incidences of both Grade II or higher complications (1/53 [1.9%] vs 9/53 [17.0%]; OR = 0.143, 95% CI: 0.015-0.656; P = 0.001) and intra-abdominal infection (0/53 [0%] vs 6/53 [11.3%]; OR = 0.073, 95% CI: 0.001-0.642; P = 0.014) than the control group. The white blood cell count on postoperative day 3 was significantly lower in the omega-3 group (P = 0.034). The cost-effectiveness analysis showed that the omega-3 group incurred an additional cost of 5,217.4 Chinese Yuan but achieved a 15.1% risk reduction in Grade II or higher complications, resulting in an ICER of 345.5. The probabilistic sensitivity analysis indicated a probability exceeding 98% that this strategy was more costly but more effective.
conclusionThis retrospective single-center study observed an association between omega-3 fish oil emulsion and attenuated postoperative inflammation and complications. Although the intervention involved higher direct medical costs, these findings provide localized evidence for optimizing perioperative nutrition support.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.